Trials / Completed
CompletedNCT03377361
An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread
A Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Metastatic Colorectal Cancers
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 325 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate treatment with nivolumab in combination with trametinib with or without ipilimumab in participants with previously treated cancer of the colon or rectum that has spread.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Nivolumab | Specified dose on specified days |
| DRUG | Trametinib | Specified dose on specified days |
| BIOLOGICAL | Ipilimumab | Specified dose on specified days |
| DRUG | Regorafenib | Specified dose on specified days |
Timeline
- Start date
- 2018-01-31
- Primary completion
- 2024-11-04
- Completion
- 2024-11-04
- First posted
- 2017-12-19
- Last updated
- 2025-12-03
- Results posted
- 2025-12-03
Locations
47 sites across 10 countries: United States, Argentina, Australia, Belgium, Canada, Chile, Czechia, Germany, Italy, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03377361. Inclusion in this directory is not an endorsement.